Bend Research Adds to Oral and Inhalation Capabilities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bend Research Adds to Oral and Inhalation Capabilities



Bend Research, part of Capsugel’s Dosage Form Solutions business unit, has added Capsugel’s Xcelodose powder-filling technology. The microdosing technology will help develop Bend Research’s recently announced Rapid Advancement of Preclinical Compounds initiative.

The Xcelodose 600S powder microdosing system enables the dispensing of dose weights as low as 100 micrograms, without excipients or bulking agents. The technology is used to prepare products for clinical trials and small-scale production.
The Xcelodose technology will have specific applications in Bend Research’s oral and inhalation product development.

Source: Bend Research

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here